Exclusive Online Content
Asahi Kasei Medical & AW Technologies Enter Exclusive Distribution Agreement for TrachFlush in Japan
AW Technologies and Asahi Kasei Medical have entered into an exclusive distribution agreement in Japan for AW Technologies’ TrachFlush device. AW Technologies is currently in the….
Oruka Therapeutics & ARCA biopharma Announce Merger Agreement
Merger to create a company focused on advancing Oruka’s portfolio of novel biologics that aim to redefine the standard of care for patients with chronic skin diseases….
Bora Pharmaceuticals Completes Acquisition of Upsher-Smith
Bora Pharmaceuticals Co. recently announced it has completed the acquisition of Upsher-Smith Laboratories, Inc., a generics manufacturer and marketer based in….
Ipsen & Sutro Biopharma Announce Exclusive Global Licensing Agreement for an ADC Targeting Solid Tumors
Ipsen and Sutro Biopharma recently announced an exclusive global licensing agreement for STRO-003, an antibody-drug conjugate in the final stages of pre-clinical development, which targets the….
Bespak Confirms Inhaled & Nasal Drug Delivery Business Separation From Recipharm
Spin-out unites three sites to create a leading global CDMO as further significant investments announced at Holmes Chapel site….
Teva & Abingworth Enter Strategic Development Funding Agreement
Collaboration combines Teva’s expertise in respiratory technology development and Launch Therapeutics’ innovative late-stage drug development model to progress Teva’s Dual-Action Asthma Rescue Inhaler (TEV-‘248) program….
Intravacc & Primrose Bio Announce Partnership to Enhance Conjugate Vaccine Development
The companies will leverage their combined experience in the development of conjugate vaccines for their clients….
Abzena Announces Major Investment in Bioconjugation & ADC Capabilities in Response to Increasing Industry Demand
Abzena recently announced a significant expansion of their Bristol, PA bioconjugate development and cGMP manufacturing site. The $5-million investment in expanded laboratory….
Vector Pharma & Oncopeptides FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East & North Africa
Oncopeptides AB and Vector Pharma FZCO recently announced a collaboration to commercialize Oncopeptides’ flagship drug Pepaxti (melphalan flufenamide) in the Middle….
Vaccinex Announces $1.5-Million Registered Direct Offering & Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
Vaccinex, Inc. recently announced it has entered into definitive agreements with certain institutional investors for the purchase and sale of 193,000 shares of its common stock in a….
Teva UK & Closed Loop Medicine Announce Strategic Partnership to Advance Development of Personalized Medicines
Teva UK Limited and Closed Loop Medicine Ltd have announced a strategic partnership to advance the development of personalized medicine. Under the agreement, Closed Loop Medicine and Teva UK will investigate….
Exothera Pledges to Fast-Track RNA Therapies With Expansion of World-First Continuous-Batch RNA Manufacturing Solution Into North America
Game-changing continuous-batch production of RNA service removes process development and scale-up steps through automation and significantly cuts clinical development time, while enhancing quality and yield….
AcedrA Biopharmaceuticals & Essential Pharma Sign Distribution Agreement to Commercialize Essential Medicines in the Middle East & North Africa Region
Essential Pharma recently announced it has signed a Distribution Agreement with AcedrA BioPharmaceuticals. This strategic collaboration aims to address unmet commercial and medical needs by….
Verge Genomics & Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy
Verge Genomics and Ferrer recently announced a strategic collaboration to co-develop VRG50635, Verge’s lead drug candidate, for the treatment of sporadic and familial forms of amyotrophic lateral sclerosis….
Pace Life Sciences Adds Liquid Capsule Filling Technology, Acquires New Jersey Laboratory From Curia & Appoints Dawn Von Rohr as Division President
Pace Life Sciences makes three major announcements for expansion of services, key acquisition, and new division Vice President….
CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study for Potential First-in-Class Therapeutic for Urea Cycle Disorders
Lead program in urea cycle disorders highlights power of CAMP4’s RAP Platform to increase gene expression using programmable, targeted medicines, with clinical candidate moving from screen-to-clinic within 3 years….
Lonza Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) From Roche
Lonza recently announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, CA, from Roche for….
Orchard Therapeutics Outlines US Launch Plans for the Only Approved Therapy for Children With Early Onset Metachromatic Leukodystrophy
Orchard Therapeutics recently announced the details of its US commercial launch of Lenmeldy (atidarsagene autotemcel), formerly known as OTL-200, the first FDA-approved therapy for the….
OKYO Pharma to Release New & Comprehensive Data GFrom Phase 2 Dry Eye Disease Trial
OKYO Pharma Limited recently announced it will be releasing new and comprehensive efficacy data readout from the Phase 2 trial of OK-101 in dry eye disease on….
ACELYRIN Announces Positive Phase 1/2 PoC Data for First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease
ACELYRIN, INC. recently announced positive proof-of-concept data from an ongoing Phase 1/2 trial of lonigutamab in thyroid eye disease (TED). Lonigutamab is a subcutaneously….
